Pharminent

Novartis reviewing options for Alcon, including possible spin-off

The Swiss pharma’s eye-care unit has struggled, spurring the review. At the same time, generic competition to Gleevec has put pressure on Novartis’ growth products.  http://www.biopharmadive.com/news/novartis-alcon-options-ipo-earnings-q4/434743/

Filed under: Company